Exosome Engineering & Drug Loading Services

Q: What types of cargo can be loaded into microbial exosomes?

We support small molecules (e.g., doxorubicin, curcumin), nucleic acids (siRNA, mRNA, miRNA, CRISPR gRNA/Cas9 RNP), proteins (enzymes, antibodies, reporter constructs), and peptides. Loading strategy is selected based on payload physicochemical properties and target application.

Q: What loading technologies do you offer, and how do I choose?

We offer endogenous genetic loading (payload expression driven by engineered plasmids or chromosomal integration in the production strain) and exogenous physicochemical loading (electroporation, heat shock, co-incubation, detergent-assisted passive diffusion). Endogenous loading is preferred for genetic cargoes and proteins that tolerate bacterial expression; exogenous loading is preferred for small molecules and sensitive nucleic acids.

Q: Can you engineer exosomes for specific cell or tissue targeting?

Yes. We employ chemical conjugation (antibodies, peptides, aptamers, small-molecule ligands) and genetic surface display (OmpA, ClyA, Lpp scaffold fusions) to direct vesicles to tumors, intestinal epithelium, immune cells, or the central nervous system. Targeting performance is validated by binding assays, confocal imaging, and flow-cytometry internalization kinetics.

Q: How is loading efficiency quantified and validated?

Loading efficiency is quantified by fluorescence intensity, HPLC, qPCR, or Western blot and normalized to total particle count or total protein. We report encapsulation efficiency (EE%), drug-to-lipid ratio, and payload molecules per vesicle. Validation includes free-drug removal confirmation, stability over storage, and functional delivery to target cells.

Q: Do you provide release kinetics and controlled-release studies?

Yes. We profile release under simulated physiological conditions (pH gradient, enzymatic digestion, temperature stress) and fit data to pharmacokinetic models. For sustained-release applications, we evaluate exosome-embedded hydrogels, microspheres, and lipid-coated formulations.

Q: Can probiotic-derived exosomes be developed for food or cosmetic applications?

Yes. We isolate exosomes from GRAS/QPS probiotic strains, optimize fermentation for yield and compliance, and develop composite formulations with GI-stability or skin-penetration validation. Documentation is prepared for food-grade or cosmetic raw-material registration.

Q: What is the typical turnaround for an integrated engineering project?

Standalone loading or surface-modification projects require 2–5 weeks. Integrated engineering-to-function projects—including loading, modification, release kinetics, and in vitro validation—typically require 6–10 weeks. In vivo pilot studies add 8–12 weeks.

Q: Do you support IND-enabling documentation and CMC packages?

Yes. We provide comprehensive CoA, SOP summaries, method validation records, batch-to-batch consistency data, and optional GxP-aligned CQA documentation suitable for IND submissions, cosmetic raw-material registration, and food-grade safety filings.

Inquiry

OverviewServicesSamplesAdvantagesApplicationsCase StudyFAQs

Overview

At Creative BioMart Microbe, we provide end-to-end engineering and drug-loading services purpose-built for microbial extracellular vesicles (mEVs), including bacterial outer membrane vesicles (OMVs), probiotic-derived exosomes, fungal EVs, and phage-derived vesicles. Our platform integrates synthetic-biology strain engineering, advanced cargo-loading technologies, precision surface modification, and release-kinetics validation into a single, milestone-driven workflow. Unlike mammalian exosome CDMOs that retrofit human cell protocols, we have optimized every loading chemistry, surface-conjugation condition, and QC assay for the unique lipidome, proteome, and immunogenic profile of microbial vesicles.

Clients receive a complete continuum from project consultation to regulatory-ready data packages. Whether you are constructing an siRNA-loaded OMV for tumor immunotherapy, developing a probiotic exosome-hydrogel composite for gut-barrier repair, or engineering a targeted BEV to deliver CRISPR components across the blood-brain barrier, our team delivers quantified loading efficiency, validated targeting performance, and mechanism-linked functional evidence that supports CMC, lot-release, and IND-enabling strategies. These services are part of our broader Microbial Exosome Services portfolio, which spans strain engineering and fermentation optimization, isolation and purification, and functional validation. Contact us for a custom project consultation.

Figure 1. Schematic overview of the integrated exosome engineering and drug-loading platform, spanning cargo-loading optimization, surface-modification engineering, release-kinetics validation, and characterization-to-function closed-loop QC.

Services

Service Workflow

Commercial end-to-end service workflow diagram for exosome engineering and drug-loading services showing seven milestone stages from project inquiry through strain assessment, cargo loading optimization, surface modification engineering, release kinetics validation, integrated characterization, and final data delivery with timeline annotations.

Inquiry

Service Details

Exosome Cargo Loading & Drug Delivery Development

We optimize cargo-loading protocols for microbial vesicles via dual-track endogenous genetic loading and exogenous physicochemical methods. Supported payloads include small molecules, nucleic acids, and proteins. Loading efficiency is quantified by fluorescence, HPLC, qPCR, or Western blot and benchmarked against empty-vesicle controls.

3D scientific illustration of exosome release kinetics profiling under pH-gradient, enzymatic, and temperature-stress conditions with pharmacokinetic curve fitting and sustained-release formulation evaluation.

Release Kinetics & Controlled-Release Validation

We profile payload release under pH-gradient, enzymatic, and temperature-stress conditions. Release curves are fitted to pharmacokinetic models. For sustained-release applications, we evaluate exosome-embedded hydrogels and lipid-coated formulations, tracking burst-effect mitigation and batch-to-batch consistency as CQAs.

3D scientific illustration of exosome surface modification engineering showing chemical conjugation and genetic display of targeting ligands, anti-phagocytic camouflage, and receptor-mediated uptake validation.

Exosome Surface Modification & Targeting Engineering

We engineer mEV surfaces via chemical conjugation and genetic display using bacterial scaffold proteins. Anti-phagocytic camouflage reduces macrophage clearance. Targeting validation includes receptor-binding assays, confocal co-localization, and flow-cytometry quantification of ligand density per vesicle.

3D scientific illustration of probiotic-derived exosome development showing GRAS strain isolation, pH-responsive hydrogel composite formulation, enteric-coated microspheres, and GI-stability validation assays.

Probiotic-Derived Exosome Development

We isolate and standardize exosomes from GRAS/QPS probiotic strains for functional-food and cosmetic applications. Composite systems include pH-responsive hydrogels and enteric-coated microspheres. GI-stability and barrier-repair potency are validated by simulated digestion and co-culture assays.

3D scientific illustration of integrated characterization and QC for engineered exosomes showing NTA, DLS, cryo-TEM, flow cytometry, and mass spectrometry analysis with pre- and post-engineering comparative data.

Integrated Characterization & QC for Engineered Exosomes

We provide pre- and post-engineering comparative characterization via NTA, DLS, cryo-TEM, flow cytometry, and mass spectrometry. Functional validation links engineering parameters to uptake efficiency, cargo transfer, and pathway activation. Deliverables include batch-to-batch consistency matrices and optional CQA documentation.

Service Specifications & QC Standards

Engineering & Loading Capability

Dual-track loading: endogenous genetic expression and exogenous physicochemical loading.
Supported payloads: small molecules, siRNA, mRNA, miRNA, CRISPR RNP, proteins, peptides, and reporter constructs.
Surface-modification strategies: chemical conjugation (NHS, maleimide, click chemistry) and genetic display (OmpA, ClyA, Lpp scaffolds).
Targeting ligands: antibodies, peptides, aptamers, small molecules, and anti-phagocytic signals.
Positive and negative controls per batch; instrument calibration with traceable standards.
Assay design aligned with MISEV2023 guidelines; GxP-compliant formats available for regulatory submissions.

Typical Data Range

Cargo-loading efficiency: 5–40% (small molecule), 1–15% (nucleic acid), 2–20% (protein).
Post-loading particle size shift: <30 nm vs. native vesicles.
Surface ligand density: 10²–10⁴ molecules per vesicle by flow-cytometry quantification.
Release half-life in simulated GI fluid: 2–12 hours depending on formulation.
Target-cell binding affinity (K_d): 10^-9–10^-7 M for antibody-mediated targeting.
Batch-to-batch loading-content CV: <15%.
Endotoxin level for in vivo-grade samples: <0.5 EU/mL.

Turnaround Time

Project Type	Timeline
Cargo-loading protocol development & optimization	2–4 weeks
Small-molecule or nucleic-acid loading	1–3 weeks
Protein loading (endogenous or exogenous)	2–4 weeks
Surface-modification engineering & validation	3–5 weeks
Release-kinetics profiling & modeling	2–3 weeks
Probiotic-derived exosome development	4–6 weeks
Integrated characterization & QC package	2–4 weeks
In vitro functional validation of engineered vesicles	3–5 weeks
Full in vivo pilot study (engineered mEVs)	8–12 weeks
Complete engineering-to-function project	10–16 weeks

Timeline may vary based on payload complexity, strain availability, and assay customization.

Deliverables

Experimental protocols and SOP summaries.
Raw data files (imaging datasets, flow-cytometry FCS files, HPLC chromatograms, MS raw data).
Processed analytical reports with statistical analysis and publication-ready charts.
Certificate of Analysis (CoA) per batch.
Methodology summary and instrument calibration records.
Release-kinetics modeling report with curve fitting and mechanism interpretation.
Bioinformatics analysis for multi-omics cargo profiling (if applicable).
Optional CQA documentation package for IND-enabling studies.

Quality Control

Batch-level instrument calibration with certified positive and negative controls.
Inter-batch consistency assessment (loading-content CV <15%, release-profile CV <20%).
MISEV2023 compliance checklist for all engineering and functional assays.
Contaminant screening for residual electroporation buffer, detergent, organic solvent, and unencapsulated free drug.
Endotoxin monitoring for all in vivo-grade samples.
Optional GxP-aligned assay validation and CQA trending analysis for lot-release documentation.

Sample Requirements

Required Information	Optional Information	Not Accepted
Sample type (purified microbial exosomes, engineered formulations, fermentation supernatants, lyophilized exosomes, conditioned media, live engineered strains) Estimated particle concentration or total protein yield Strain background and culture conditions Sample volume (≥500 μL recommended for in vitro; ≥1 mL for multi-omics; ≥10 mL for large-scale loading) Endotoxin level (for in vivo studies) Target payload (if loading service requested) Desired functional endpoints or mechanism hypotheses	Prior isolation method (TFF, SEC, ultrafiltration, density gradient, or other) Target application (research, CMC, regulatory filing, publication, food-grade, cosmetic-grade) Payload type and concentration (for loading projects) Surface-modification target (cell type, tissue, receptor) Special engineering requests (fluorescent labeling, reporter gene loading, biotin/click-chemistry handles, in vivo imaging compatibility) Control sample requirements (untreated, vehicle-only, empty vesicle, or competitor benchmark) Regulatory documentation requirements (CoA, SOP, CQA package)	Samples subjected to more than three freeze-thaw cycles Samples with unidentified strain origin or undocumented culture conditions Severely degraded, contaminated, or detergent-heavy preparations Samples preserved with fixatives, antimicrobial agents, or non-sterile buffers Samples shipped at inadequate temperature or with compromised cold-chain documentation

Recommended Sample Quantity by Application:

Application	Recommended Amount
Cargo-loading optimization	≥200 μg total protein or 2×10⁹ particles
Small-molecule loading	≥300 μg total protein
Nucleic-acid loading	≥500 μg total protein
Protein loading (endogenous)	≥1×10¹⁰ particles or engineered strain culture
Surface-modification validation	≥200 μg total protein
Release-kinetics profiling	≥500 μg total protein
Probiotic-derived exosome development	≥1 L fermentation supernatant or ≥500 μg purified EVs
In vitro functional validation	≥300 μg total protein
In vivo pilot studies	≥1 mg total protein
Full in vivo efficacy studies	≥2–5 mg total protein
Biodistribution studies	≥1 mg labeled exosomes

Storage & Shipping: Ship frozen at –80°C on dry ice. Store at –80°C upon receipt. Avoid repeated thawing. Recommended buffer: sterile PBS, pH 7.4, endotoxin-free. Live engineered strains should be shipped on glycerol stocks or agar stabs with cold-chain documentation.

Inquiry

Our Advantages

Microbial EV Engineering Specialization: Deep expertise in bacterial OMVs, probiotic EVs, and fungal vesicles. Every loading chemistry and surface-conjugation protocol is optimized for microbial membrane composition, not adapted from mammalian templates.
Dual-Track Loading Platform: Endogenous genetic loading and exogenous physicochemical loading operate in parallel, enabling flexible payload matching across small molecules, nucleic acids, proteins, and CRISPR complexes with quantified efficiency.
Modular Surface-Engineering Toolkit: Chemical conjugation and genetic display strategies are offered as interchangeable modules, supporting targeting, immune evasion, tracking, and multi-ligand presentation from a single production run.
Loading-to-Release-to-Function Closed-Loop Validation: Engineered vesicles are not released after loading quantification alone. We validate release kinetics, target-cell uptake, cargo functional transfer, and pathway activation in a single integrated report.
Regulatory-Ready & Scale-Up Compatible: Documentation supports CMC packages and IND-enabling studies. Upstream fermentation and downstream purification are designed for GMP-compatible scale-up from milligram to gram-scale production.

Applications

Therapeutic drug delivery system development application icon showing engineered microbial extracellular vesicles targeting tumor, inflamed tissue, or infection sites.

Therapeutic Drug Delivery System Development

Engineered mEVs loaded with chemotherapeutics, nucleic-acid therapeutics, or protein drugs for targeted delivery to tumors, inflamed tissues, or infection sites.

Vaccine adjuvant and antigen delivery engineering application icon showing OMV-based adjuvant optimization and immunomodulatory mechanism validation.

Vaccine Adjuvant & Antigen Delivery Engineering

OMV-based adjuvant optimization, antigen surface display, and immunomodulatory mechanism validation for next-generation bacterial and viral vaccines.

Probiotic and functional food-grade exosome development application icon showing GRAS strain isolation and GI-stability validation.

Probiotic & Functional Food-Grade Exosome Development

GRAS/QPS probiotic exosome isolation, composite formulation, GI-stability validation, and potency assessment for functional-food and nutraceutical applications.

Cosmetic and skin-targeted delivery systems application icon showing skin-barrier penetration and anti-inflammatory functional validation.

Cosmetic & Skin-Targeted Delivery Systems

Skin-barrier penetration, anti-inflammatory and barrier-repair functional validation, and cosmetic raw-material compliance documentation.

Case Study

Case Study 1: Enzyme-Powered Bacterial Outer Membrane Vesicle Nanorobots for Enhanced Tumor Therapy

Researchers developed fully biocompatible nanorobots by integrating urease with bacterial outer membrane vesicles (OMVs). The OMV body was genetically engineered to surface-express cell-penetrating peptide (CPP) via ClyA fusion for tumor targeting and penetration. siRNA was loaded through electroporation and protected from RNase and serum degradation by the intact OMV membrane. Urease immobilized on the membrane catalyzed urea decomposition to generate self-diffusiophoretic propulsion. In an orthotopic bladder tumor model, intravesical instillation of OMV-siR robots demonstrated enhanced tumor binding and deep tissue penetration compared to static controls. The nanorobots significantly increased mature dendritic cells, CD4⁺ and CD8⁺ T cells, and macrophage infiltration while elevating proinflammatory cytokines. Western blot and immunohistochemistry confirmed lowest survivin expression in the nanorobot group. Bioluminescence imaging showed negligible tumor signal by day 28, with complete mouse survival and no systemic toxicity. This illustrates the synergistic potential of genetic surface engineering, cargo loading, and active propulsion for precision tumor therapy.

Schematic of motion-enhanced gene silencing and immune stimulation by urease-powered OMV nanorobots with CPP surface engineering for targeted bladder cancer therapy.
Figure 2. Motion-enhanced gene silencing and immune stimulation mechanism of OMV-siR robots. (Tang, et al. 2024)

Case Study 2: Metal Ion-Anchored OMVs for Ferroptosis-Immunotherapy in Colon Tumor

Researchers engineered bacterial outer membrane vesicles (OMVs) by anchoring ferrous ions via electrostatic interactions, loading STING agonist-4, and decorating with DSPE-PEG-FA for tumor targeting (OMV/SaFeFA). Fe²⁺ anchoring endowed peroxidase-like activity to catalyze H₂O₂ to OH, inducing lipid peroxidation and ferroptosis. The platform demonstrated pH-responsive release of Fe²⁺ and agonist at tumor sites. In MC38 colon tumor-bearing mice, systemic OMV/SaFeFA administration achieved 77.6% tumor weight inhibition and 66.3% survival at day 58, with no acute toxicity. Mechanistically, STING activation in dendritic cells enhanced IFN-γ production, which suppressed SLC7A11 and GPX4 to amplify ferroptosis. Flow cytometry confirmed elevated intratumoral CD8⁺ and CD4⁺ T cells and mature DCs. This demonstrates the therapeutic potential of multifunctional OMV engineering combining metal ion functionalization, immune adjuvant loading, and active targeting for synergistic tumor therapy.

Schematic of metal ion-anchored bacterial outer membrane vesicles loaded with STING agonist and folate-targeted decoration for ferroptosis induction and immune activation in colon tumor therapy.
Figure 3. Engineering and mechanism of OMV/SaFeFA for tumor ferroptosis and immunotherapy. (Sun, et al., 2024)

FAQs

Q: What types of cargo can be loaded into microbial exosomes?

A: We support small molecules (e.g., doxorubicin, curcumin), nucleic acids (siRNA, mRNA, miRNA, CRISPR gRNA/Cas9 RNP), proteins (enzymes, antibodies, reporter constructs), and peptides. Loading strategy is selected based on payload physicochemical properties and target application.

Q: What loading technologies do you offer, and how do I choose?

A: We offer endogenous genetic loading (payload expression driven by engineered plasmids or chromosomal integration in the production strain) and exogenous physicochemical loading (electroporation, heat shock, co-incubation, detergent-assisted passive diffusion). Endogenous loading is preferred for genetic cargoes and proteins that tolerate bacterial expression; exogenous loading is preferred for small molecules and sensitive nucleic acids.

Q: Can you engineer exosomes for specific cell or tissue targeting?

A: Yes. We employ chemical conjugation (antibodies, peptides, aptamers, small-molecule ligands) and genetic surface display (OmpA, ClyA, Lpp scaffold fusions) to direct vesicles to tumors, intestinal epithelium, immune cells, or the central nervous system. Targeting performance is validated by binding assays, confocal imaging, and flow-cytometry internalization kinetics.

Q: How is loading efficiency quantified and validated?

A: Loading efficiency is quantified by fluorescence intensity, HPLC, qPCR, or Western blot and normalized to total particle count or total protein. We report encapsulation efficiency (EE%), drug-to-lipid ratio, and payload molecules per vesicle. Validation includes free-drug removal confirmation, stability over storage, and functional delivery to target cells.

Q: Do you provide release kinetics and controlled-release studies?

A: Yes. We profile release under simulated physiological conditions (pH gradient, enzymatic digestion, temperature stress) and fit data to pharmacokinetic models. For sustained-release applications, we evaluate exosome-embedded hydrogels, microspheres, and lipid-coated formulations.

Q: Can probiotic-derived exosomes be developed for food or cosmetic applications?

A: Yes. We isolate exosomes from GRAS/QPS probiotic strains, optimize fermentation for yield and compliance, and develop composite formulations with GI-stability or skin-penetration validation. Documentation is prepared for food-grade or cosmetic raw-material registration.

Q: What is the typical turnaround for an integrated engineering project?

A: Standalone loading or surface-modification projects require 2–5 weeks. Integrated engineering-to-function projects—including loading, modification, release kinetics, and in vitro validation—typically require 6–10 weeks. In vivo pilot studies add 8–12 weeks.

Q: Do you support IND-enabling documentation and CMC packages?

A: Yes. We provide comprehensive CoA, SOP summaries, method validation records, batch-to-batch consistency data, and optional GxP-aligned CQA documentation suitable for IND submissions, cosmetic raw-material registration, and food-grade safety filings.

References:

Tang, S., et al. (2024). Bacterial outer membrane vesicle nanorobot. Proceedings of the National Academy of Sciences, 121(30), e2403460121.
Sun, Y., et al. (2024). Metal ions-anchored bacterial outer membrane vesicles for enhanced ferroptosis induction and immune stimulation in targeted antitumor therapy. Journal of Nanobiotechnology, 22(1), 474.

Services

Inquiry